Abstract
PURPOSE: To evaluate the long-term results of modified catheterization technique (Mo-CAT) for percutaneous treatment of liver CE2/CE3b hydatid disease in a large series. MATERIALS AND METHODS: A total of 119 patients (F/M:73/59) and 132 liver CE2 and CE3b cysts who underwent percutaneous treatment by Mo-CAT from 2009 to 2020 were included in the study. Patients' age ranges from 8 to 78 years (mean: 39 years). Volume changes of all cysts after the procedure, success and complication rates, duration of hospital stay, catheterization time and recurrence rates were recorded. Technical success was defined as successful catheter introduction into the CE. Clinical success was defined as cases with no mortality and no recurrence. RESULTS: Among all patients, the mean reduction in the cyst volume was 65.84% (range 6.29-100%). The mean length of hospital stay was 3.88 ± 4.73 days (range 1-36 days). A total of 107 (89.9%) of 119 patients were discharged from the hospital in first the week after the procedure. Major complications were observed in 12 of 119 patients (10.08%) and 12 out of 132 cysts (9.09%). Recurrence was detected in 6 (4.5%) cysts in 6 patients (4.5%) who needed additional procedures. Among all 119 patients, the mean follow-up duration was 51.66 ± 35.56 months (median, 49.00 months; range 0-131 months). CONCLUSIONS: Treatment of liver CE2/3b with Mo-CAT appears to be a safe, reliable and efficient technique which is associated with low recurrence and complication rates.